Recently, the existence of significant deposits of brown adipose tissue (BAT) in human adults was confirmed. Its role in the human metabolism is unknown but could be substantial. Inhibition of the cannabinoid receptor-1 (CB1) by the antagonist rimonabant (SR141716) has been associated with activation of BAT thermogenesis and weight loss in mice and rats. The role of peripheral and central CB1 in the activation of BAT merits further investigation. Here we developed a technique for quantifying CB1 in BAT by PET. Methods: Sections of rat BAT and subcutaneous white adipose tissue (WAT) were stained for CB1 and uncoupling protein-1 by immunofluorescent staining. Binding of the ra-
tissue (BAT) in human adults was confirmed (1) . Its influence on the whole-body metabolism and energy expenditure in humans is currently unknown, but based on extensive experience in rodents it could be substantial (2) . Quantitative noninvasive measurements of cold activated BAT glucose utilization amount to 12.2 mmol/100 g of BAT/min, and given that the primary energy source for BAT is fatty acids, the true energy expenditure may be higher (1) . Consequently, pharmaceutical means for inducing subcutaneous white adipose tissue (WAT) to BAT conversion (browning) as well as BAT activation are pursued for the treatment of obesity.
It has been shown that chronic inhibition of the cannabinoid receptor-1 (CB1) by the antagonist rimonabant (SR141716) is associated with activation of BAT thermogenesis and weight loss in mice and rats (3, 4) . These effects were shown to be mediated by both peripheral CB1 (5) and CB1 located in the central nervous system (CNS) (4) .
Furthermore, chronic treatment by rimonabant induced an increase in uncoupling protein-1 (UCP-1) in WAT and initiated a transdifferentiation into a brown fat phenotype (6) . Clearly, the role of peripheral and central CB1 in the activation of BAT merits further investigation.
However, the clinical translation of these interesting results has been hampered by the lack of methodologies for the noninvasive in vivo study of peripheral CB1. The PET ligand (3R,5R)-5-(3-(18F-fluoromethoxy)phenyl)-3-(((R)-1-phenylethyl)amino)-1-(4-(trifluoromethyl)-phenyl)pyrrolidin-2-one ( 18 F-FMPEP-d 2 ) has previously been validated for quantification of CB1 availability and occupancy in the CNS in humans (7) .
In this study, we investigated the feasibility of assessing CB1 availability in deposits of BAT using 18 F-FMPEP-d 2 PET.
MATERIALS AND METHODS

Staining for CB1 and UCP-1 in Adipose Tissue
BAT and subcutaneous WAT were excised from Sprague-Dawley rats after euthanasia. The tissue samples were immediately snap-frozen, mounted in Tissue-Tec (Sakura), and processed into 10-mm sections by a Microtome (Microm) and placed on object glasses.
The sections were fixed in ice-cold acetone for 10 min and then blocked with DAKO serum-free protein block for 60 min (Agilent Technologies). The sections were then incubated overnight at 4°C with either an anti-UCP-1 antibody (Ab#10983 [Abcam]; dilution, 1:500) or an anti-CB1 antibody (Ab#23703 [Abcam]; dilution, 1:300) and then incubated with the secondary antibody Alexa fluor 555 (Invitrogen; donkey antirabbit; dilution, 1:1,000) for 60 min in a humidified dark chamber. The slides were mounted with ProLong Gold Antifade reagent with 49,6-diamidino-2-phenylindole (DAPI) (Life Technologies). Adjacent frozen sections were fixed in ethanol and stained with hematoxylin and eosin. Images were acquired with a Zeiss LSM780 confocal microscope at 20· magnification. The sections stained for UCP-1 were assigned a green pseudocolor.
Radiochemistry 18 F-FMPEP-d 2 was synthesized as described previously (8) . The radiochemical purity was greater than 95% and the specific radioactivity greater than 500 GBq/mmol at the end of synthesis.
In Vitro Autoradiography
Biopsies of intrascapular BAT (iBAT) and subcutaneous WAT from Sprague-Dawley rats were frozen to 280°C and processed into 10-mm sections. To study tracer binding properties to the tissue, the sections were incubated in concentrations in the nanomolar range (0.05-1.5 nM) of 18 F-FMPEP-d 2 in 50 mM Tris-HCl (pH 7.6) for 90 min at room temperature. Nondisplaceable binding was assessed by adding 10 mM of the CB1 antagonist rimonabant (rimonabant hydrochloride; Sigma-Aldrich) 10 min before 18 F-FMPEP-d 2 . Tissue slices were then washed 3 times for 4 min in 50 mM ice-cold Tris to remove excess tracer and then air-dried. The sections were exposed against a phosphor-imager screen (Fuji BAS-TR2025; Fuji Photo Film Co.) for 3 h, digitalized using a BAS-5000 Fuji scanner (Fujifilm Life Science), and analyzed using the AIDA 4 (Raytest) software.
Organ Distribution Studies
Sprague-Dawley rats (n 5 12, male; age, 8-10 wk; weight, 292 6 24 g) were housed under standard laboratory conditions with free access to food and water. All handling and experiments were performed in accordance with the national guidelines and were approved by the local ethics committee for animal research. All applicable institutional or national guidelines for the care and use of animals were followed.
18 F-FMPEP-d 2 (9.6 6 2.3 MBq, corresponding to 33.2 6 9.2 MBq/kg or in all cases , 0.1 mg/kg, adhering to the tracer concept) was administered intravenously in the tail in rats sedated by isoflurane. Anesthesia was induced by 4% isoflurane in 600 mL air/min and maintained by 2.5% isloflurane in 400 mL air/min. The animals were maintained under anesthesia and sacrificed at different time points: 5, 15, 30, 60, 90, and 120 min. Tissues were excised and measured for radioactive content in a well counter and corrected for weight, and radioactive uptake was expressed as percentage injected dose per gram of tissue.
Portions of the iBAT deposit, the CNS cortex, subcutaneous WAT, and blood plasma were taken for analysis of radioactive metabolites as described below.
Metabolite Analysis
Metabolite analysis was performed on tissues from 6 animals at 6 different time points: 5, 15, 30, 60, 90, and 120 min.
Samples from iBAT, cortex, and subcutaneous WAT was homogenized in 1% trifluoroacetic acid (TFA)/acetonitrile in 2-mL borosilicate tubes using a pestle. The liquid containing homogenates was transferred to 2-mL Eppendorf tubes. Blood plasma (250 mL) was mixed with 350 mL of 1% TFA/acetonitrile in a 2-mL Eppendorf tube.
All samples were centrifuged at 4,500 rpm for 4 min, and the supernatant was transferred to a new Eppendorf tube. Additional 1% TFA/acetonitrile was added, and the centrifugation was repeated until the resulting liquid was clear.
Aliquots (10-20 mL) of each tissue homogenate and a 2-mL reference of 18 F-FMPEP-d 2 in human plasma were added to a thin-layer chromatography plate. One percent TFA (5 mL) was added to cover the bottom centimeter of a glass vat, and the thin-layer chromatography plate was placed standing in the buffer. The plate was left for approximately 1 h until the buffer had reached the 5-cm mark.
The plate was then dried and exposed against a digital autoradiographic plate (Fuji BAS-TR2025; Fuji Photo Film Co.) for more than 2 h and then scanned in a BAS-5000 Fuji scanner (Fujifilm Life Science). The autoradiograms of the radioactive 18 F-FMPEP-d 2 metabolites were analyzed by AIDA 4 (Raytest). Peaks were integrated and background levels subtracted. The peak corresponding to native, unchanged 18 F-FMPEP-d 2 ligand was identified by comparison with the reference. The percentage of unchanged 18 F-FMPEP-d 2 in each sample was determined by calculating the contribution of the area of this peak compared with the total integrated area of all peaks.
The percentage of native 18 F-FMPEP-d 2 in all tissues over time was further analyzed in GraphPad Prism 5.04 (GraphPad Software). The metabolism in blood plasma was fitted to a monoexponential function for further use in the construction of an input function for tracer kinetic analysis.
PET Imaging Procedures
Seven of the animals were examined by a preclinical PET/CT scanner (Inveon PET/CT; Siemens). The animals were positioned by CT, with the brain and the abdomen in the 127-mm axial field of view.
The animals were then examined by PET in list-mode for 120 min from injection of 18 F-FMPEP-d 2 .
PET data were reconstructed into the frame sequence 11 · 10, 1 · 20, 5 · 30, 1 · 45, 4 · 60, 1 · 330, 2 · 600, 1 · 900, and 4 · 1,200. Images were acquired in 3-dimensional mode and reconstructed using an iterative ordered-subset expectation maximization 2-dimensional algorithm.
PET Analysis
Reconstructed data were analyzed by PMOD (PMOD Technologies Ltd.). Regions of interest of select tissues were delineated on coregistered transaxial CT slices.
The left heart ventricle was used as a model for arterial tracer content and as a basis for an input function for kinetic tracer analysis. The left ventricle was delineated on early PET time frames in combination with CT images to avoid mismatch due to breathing movement artifacts. iBAT, subcutaneous WAT, and CNS cortex were delineated on timesummated PET images and corresponding coregistered CT images. Cortical bone was delineated in the skull to assess the extent of tracer defluorination also seen in the organ distribution study.
Time-activity curves (TACTs) (expressed as kBq/mL) in all the described tissues were then generated for the full 120-min sequence.
The individual left ventricle TACT was used as a model for whole arterial blood. The plasma-to-blood ratio was extrapolated by fitting a monoexponential function to data from the ex vivo organ distribution (5-to 120-min time points). This correction was then applied to each individual left ventricle TACT.
A monoexponential curve was similarly fitted to the data from the plasma metabolite data. This function, describing the percentage of unchanged 18 F-FMPEP-d 2 ligand in plasma on a population level, was then applied as a final correction to generate a metabolite-corrected arterial plasma curve for use as an input function for tracer kinetic modeling.
The TACTs of iBAT, cortex, and subcutaneous WAT were used as output data in the PMOD kinetic modeling module (PKIN; PMOD Technologies). One-and 2-tissue-compartment (1TC and 2TC, respectively) models (with variable vascular contribution, Vb, as a parameter) were applied to each tissue using the metabolitecorrected arterial plasma curve as input, and the uncorrected individual left ventricle TACT was used as a model for arterial whole-blood and vascular contribution. Tissue uptake of tracer was expressed as total volume of distribution (Vt) or volume of distribution of the second compartment (Vs, interpreted as receptor specific binding).
RESULTS
CB1 in Adipose Tissue
Sections of iBAT were positive for immunostaining with CB1 (Fig. 1A) as well as UCP-1 (Fig. 1C) . Predictably, UCP-1 staining was negative in WAT sections (Fig. 1D) . WAT samples were also negative for CB1 immunostaining (Fig. 1B) . Hematoxylin and eosin staining of adjacent sections confirmed the distinct morphology of BAT (Fig. 1E) and WAT (Fig. 1F) .
In Vitro Autoradiography
Displaceable, or CB1-mediated, binding was approximately 10-fold higher in sections of BAT than WAT (P , 0.01; 18 F-FMPEP-d 2 concentration, 0.5-1.5 nM; Fig. 2A ). 18 F-FMPEP-d 2 binding in iBAT, but not WAT, could be blocked by coincubation with the CB1 antagonist rimonabant. Saturation of binding occurred at nanomolar concentrations of 18 F-FMPEP-d 2 , with a corresponding estimated receptor density of 667 fmol CB1s per microgram of BAT tissue (Fig. 2B) . No appreciable CB1-specific binding was found in WAT at either tracer concentration used, thus neither dissociation constant nor receptor density could be estimated (Fig. 2C) .
PET Quantification of CB1 in Rats
iBAT deposits were clearly identifiable on PET images (dark blue region, Fig. 3A) . A high accumulation of radioactivity was also seen in cortical bone (light blue region), most likely corresponding to incorporation of ionic 18 F 2 in hydroxyapatite in bone tissue. The free ionic 18 F 2 was likely due to species-specific defluorination of 18 F-FMPEP-d 2 . Red regions in Figure 3B indicate subcutaneous WAT. Ex vivo organ distribution confirmed marked accumulation of radioactivity in iBAT and brain including the cortex (Fig. 3C) . Accumulation in subcutaneous WAT was lower than for iBAT 120 min after administration, consistent with the immunostaining (P , 0.001). The residual tracer accumulation in WAT, despite an almost complete lack of CB1 expression, is likely due to nonspecific binding because of the relatively high lipophilicity of 18 F-FMPEP-d 2 .
The plasma-to-whole-blood ratio was best estimated by a monoexponential decay function (described by the parameters Y 0 5 1.56, k 5 0.025, and plateau 5 1.35).
Metabolite analysis showed that radioactive uptake in iBAT, cortex, and subcutaneous WAT originated almost exclusively from unchanged 18 F-FMPEP-d 2 for the duration of the experiment (5-120 min) (Fig. 3D) . The metabolic degradation of 18 F-FMPEP-d 2 in blood plasma followed a monoexponential decay function (described by the parameters Y 0 5 100, k 5 0.038, and plateau 5 37.9). A 2TC model best described tracer kinetics in iBAT and CNS cortex in all subjects, based on minimization of x 2 (BAT x 2 , 5.2 6 2.3; cortex x 2 , 5.0 6 2.2). There was no difference between Vs and Vt between these tissues, indicating a similar amount of available receptors. A 1TC model best described the tracer kinetics in subcutaneous WAT, whereas the 2TC model did not converge. The same 1TC model could also reasonably well describe the kinetic behavior in iBAT (x 2 , 7.7 6 2.9). A comparison between WAT and BAT was therefore performed using the 1TC model. There was a significant difference in Vt between WAT and iBAT (Fig. 3E) . There was no difference in the vascular contribution. The difference in Vt was due to a higher K 1 and to a lesser extent k 2 in iBAT compared with WAT.
DISCUSSION
Here, we have shown the feasibility of noninvasive assessment of the CB1 in deposits of BAT in a rodent model. The implications of this are several, both for development of novel approaches for activating BAT and for quantifying BAT mass (both native and induced) in vivo.
Systemically administration of CB1 antagonists, most notably rimonabant, has been shown to induce weight loss in humans. This effect can be attributed partly to induction of satiety by CB1 antagonism in the CNS (9). More recently it was also shown that peripheral CB1 antagonism increased energy expenditure in rodents, with subsequent weight FIGURE 1. Immunohistochemistry of CB1 and UCP-1 in iBAT and WAT. BAT was positive for CB1 (A) and for UCP-1 (C). WAT, on the other hand, was negative both for CB1 (B) and for UCP-1 (D). Hematoxylin and eosin (HTX) staining of adjacent sections confirmed distinct morphology of BAT (E) and WAT (F). Scale bar indicates 100 μm. loss (10) . The unwanted side effects of CB1 antagonism are exclusively centrally mediated and include severe ones such as suicidal ideation. Consequently, development of rimonabant for weight loss purposes was discontinued. Currently, novel CB1 antagonists with limited penetration of the blood-brain barrier (BBB) are being developed to exploit the peripherally mediated weight loss while avoiding the centrally mediated side effects.
We proposed that the methodology described in this study can be used to further understand the function of CB1 in BAT, including assessment of CB1 up-or downregulation during acute or chronic activation of BAT induced either by cold or by pharmaceutical intervention (e.g., adrenoreceptor agonism, irisin). Additionally, it is likely feasible to directly evaluate the receptor occupancy in BAT by novel non-BBB-penetrating CB1-targeted antagonists and the correlation between CB1 occupancy and BAT activation. Indeed, it was recently reported that intravenous pretreatment with the CB1 antagonist TM388837 induced a decreased binding of 18 F-FMPEP-d 2 in presumed BAT in nonhuman primates (11) .
The presence of BAT in human adults is highly heterogeneous between individuals and difficult or impossible to predict without imaging methodologies. Currently, the only method for confirming BAT in individual humans is the examination of cold-induced glucose utilization in the supraclavicular regions by PET. Recently, it was also shown that BAT activated by b3 adrenergic receptor agonism can be measured in a similar manner (12) . With the use of these advanced methodologies, it has been found that BAT is more prevalent in some populations, such as young, lean women, and rare in other groups, such as obese persons. These correlations are remarkable in themselves, but it is currently not known if lack of BAT is caused by long-standing obesity (e.g., some form of BAT exhaustion) or if the absence of endogenous BAT from an early age predisposes humans toward the development of obesity later in life.
Here, we proposed the CB1 as an imaging biomarker for the presence of BAT. Both immunohistochemistry and PET results presented here show that CB1 is colocalized with BAT or the exclusive BAT marker UCP-1 both in rodents and in humans. Importantly, subcutaneous WAT is almost devoid of CB1, suggesting that CB1 can be used as a surrogate marker for the UCP-1 and consequently BAT deposits. This is, to our knowledge, the first study to show extensive CB1 density in BAT. However, gene expression studies have reported CB1 expression across several tissues previously including BAT, at least in mice, in which CB1 was not overexpressed compared with WAT (13) . The CB1 gene expression levels in human BAT are currently unknown.
The radioligand 18 F-FMPEP-d 2 can identify CB1-rich peripheral regions including BAT without the elaborated cold treatment required for the detection of BAT by 18 F-FDG PET. Presently, it is unknown whether CB1 is expressed in similar amounts in each brown adipocyte or if there are large differences. This must be further evaluated for understanding the potential of CB1 as a surrogate marker for BAT mass in vivo.
Other limitations of the current study include the translation from rodents to humans. 18 F-FMPEP-d 2 exhibits high defluorination with subsequent uptake in bone in rats. In humans, however, this is not seen in appreciable amounts. In fact, the reason for the deuteration of the tracer was intended to decrease the rate of defluorination.
Because of the marked difference in CB1 expression, 18 F-FMPEP-d 2 can potentially differentiate between BAT and WAT. White to brown fat conversion (browning) is a key step for exploring the potential use of BAT activation in obesity treatment. Only few reports on detection of browning in vivo have been reported, including the use of the norepinephrine transporter as a surrogate imaging biomarker due to the extensive sympathetic innervation of BAT (14) (15) (16) . However, the activity and up-and downregulation of norepinephrine transporter and other components of the noradrenergic system are tightly connected to the activation of BAT. For example, induction of anesthesia completely blunts both the activation of BAT and the use and uptake of norepinephrine transporter by substrates such as ephedrine (15, 17) . It is therefore likely that the 11 C-hydroxyephedrine PET quantitation methodologies can underestimate the amount of BAT or browning deposits in WAT under several physiologic conditions. We therefore instead propose to further validate 18 F-FMPEP-d 2 as a robust PET marker for detection of induced browning. 
